爱尔康BRYTLY去红血丝眼药水获FDA批准 一分钟起效、效果最长12小时
日内瓦讯——眼科护理公司爱尔康（Alcon，纽交所：ALC）10月16日经Business Wire宣布，其BRYTLY去红血丝眼药水已获美国食品药品监督管理局（FDA）批准。BRYTLY用于减轻眼部红血丝，预计未来数月内在主要零售商及线上渠道上市。
据公司公告，BRYTLY滴后一分钟起效，可让眼睛看起来更白净的效果最长达12小时；按公告引用的标签表述，其效果时长比Lumify最长多出约50%。
爱尔康总部位于瑞士日内瓦，在纽约证券交易所上市，是全球眼科护理产品企业之一，业务涵盖眼科手术设备与视力保健产品。此次获批为其非处方眼药产品线新增一款去红血丝产品。
Alcon's BRYTLY Redness Reliever Eye Drops Win FDA Approval, Working in One Minute for Up to 12 Hours
GENEVA — Alcon (NYSE: ALC) announced on October 16 via Business Wire that the U.S. Food and Drug Administration has approved BRYTLY Redness Reliever Eye Drops. The product is designed to reduce eye redness and is expected to become available at major retailers and online in the coming months.
According to the company's release, BRYTLY works in one minute and delivers up to 12 hours of whiter-looking eyes. The release also said the product lasts up to 50 percent longer than Lumify, based on the cited label claims.
Alcon, headquartered in Geneva, Switzerland, and listed on the New York Stock Exchange, is a global eye-care company whose businesses span surgical equipment and vision care products. The approval adds a new redness reliever to its over-the-counter eye drop lineup.
发布：GSM·美国（发布链接）
图片来源：爱尔康公司资料图（Wikimedia Commons） / Alcon company image (Wikimedia Commons)
GSM Global · 本篇英文版 English edition of this story
